NCT04057703
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with Chronic Immune Thrombocytopenic Purpura (a condition where the immune system attacks platelets), Autoimmune Hemolytic Anemia (a condition where the immune system attacks red blood cells), or Evans Syndrome (both conditions occurring at the same time).
- You are starting your first second-line treatment (meaning a second attempt at treatment after the first approach) using one of these specific medicines: azathioprine, ciclosporine, eltrombopag, hydroxychloroquine, mycophenolate mofetil, rituximab, or romiplostim.
- You are already registered in a specific patient database called OBS'CEREVANCE.
Who may not be able to join:
- You are already taking immune-suppressing medication for a different immune system condition at the time you start this new second-line treatment.
- You are starting two different second-line treatments on the exact same day.
- You, or your legal guardian if applicable, have said you do not wish to take part in the study after reading the information provided about it.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Primary endpoints
Haemorrhagic sign - Grade ≥ 3 (Buchanan score) Presence of a haemorrhagic sign ≥grade 3; Thrombocytopenia Presence of thrombocytopenia <30 G / L; Need of a transfusion ?; Immunoglobulin IV Immunoglobulin IV; Corticoids push; Need a splenectomy ?; Clinical signs of anemia; Anemia; Introduction of a new immunomodulatory treatment; Stop treatment or not ?
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.